Background and Objectives Dipeptidyl peptidase-4 (DPP4) inhibition is a potential strategy to increase the engraftment rate of haematopoietic stem/progenitor cells. A recent clinical trial using sitagliptin, a DPP4 inhibitor approved for type 2 diabetes mellitus, has been shown to be a promising approach in adults with haematological malignancies after umbilical cord blood (UCB) haematopoietic cell transplantation (HCT). On the basis of data from this clinical trial, a semi-mechanistic model was developed to simultaneously describe DPP4 activity after multiple doses of sitagliptin in subjects with haematological malignancies after a single-unit UCB HCT.
Introduction
Sitagliptin is a dipeptidylpetidase-4 (DPP4) inhibitor approved for use in type 2 diabetes mellitus. DPP4 inhibition leads to decreased cleavage of endogenous incretins, indirectly improving glucose homeostasis [1] . However, DPP4 (also known as CD26) truncates other endogenous proteins, including the cytokine stromal-derived factor-1a which, in combination with its receptor, CXCR4, plays a critical role in chemotaxis and engraftment of haematopoietic stem/progenitor cells [2] [3] [4] , as well as colony-stimulating factors, which are growth factors for haematopoiesis [5] .
Use of umbilical cord blood (UCB) in haematopoietic cell transplantation (HCT) has been limited because of delayed engraftment, resulting in increased morbidity and mortality [6] [7] [8] . Pre-clinical studies in mice have shown that inhibition of DPP4 enhances stem cell engraftment [5] . A recent trial (clinicaltrials.gov identifier NCT00862719) investigated the feasibility, safety and potential efficacy of systemic inhibition of DPP4, using sitagliptin to enhance engraftment of single-unit UCB transplants in adults with haematological malignancies [9] . While prior studies (which are summarized in Table 1 ) [9] [10] [11] [12] [13] [14] [15] [16] [17] , had extensively explored the pharmacokinetics of sitagliptin and DPP4 inhibition, this had not been done in a population of recipients undergoing HCT [10, 11, [14] [15] [16] [17] . Surprisingly, this trial [9] did not achieve the extent of sustained inhibition of plasma DPP4 activity (greater than 90 % plasma DPP4 inhibition for 24 h) that had previously been observed in healthy volunteers [10, 15] . In the HCT population, sitagliptin exposure, as measured by the maximum plasma drug concentration (C max ) and the area under the plasma drug concentration-time curve (AUC) from time zero to infinity (AUC 0-? ), was approximately half that previously observed in non-HCT populations. These differences highlight the need for a quantitative description of sitagliptin pharmacokinetics and DPP4 inhibition during HCT.
Population pharmacokinetic-pharmacodynamic models can facilitate clinical development of DPP4 inhibition for acceleration of engraftment. On the basis of data from a pilot UCB HCT study in adult patients with leukaemia and lymphoma [9] , we developed a semi-mechanistic model that simultaneously describes sitagliptin pharmacokinetics and DPP4 activity after multiple doses of sitagliptin. The model-based approach to understanding sitagliptin concentrations and DPP4 activity provides an opportunity to explore and optimize the dose and dosing schedule for this novel approach to enhance engraftment of UCB cells from a single UCB unit in adult patients.
Methods

Study Design
The full details of the clinical trial have been published by Farag et al. [9] , but design issues that are salient to the trial are as follows. The trial was approved by the Indiana University Institutional Review Board and was registered at ClinicalTrials.gov (identifier NCT00862719). All patients gave written informed consent. Twenty-four adult patients who had advanced haematological malignancies, a Karnofsky performance status C70 and adequate end-organ function, but lacked human leukocyte antigen (HLA)-identical or wellmatched unrelated donors, were enrolled in the clinical trial. The preparative regimen consisted of 13.2 Gy total body irradiation in eight fractions on days -7 to -4, cyclophosphamide 60 mg/kg on days -3 to -2 and rabbit antithymocyte globulin 2.5 mg/kg on days -4 to -2. After 11 patients were recruited, antithymocyte globulin was replaced with fludarabine 30 mg/m 2 on days -4 to -2. Single units of UCB were infused on day 0. Prophylaxis against graft-versus-host disease was deployed using sirolimus and tacrolimus. Filgrastim 5 lg/kg/day was administered subcutaneously on day ?5 until neutrophil recovery. Sitagliptin 600 mg once daily (OD) was administered on days -1 to ?2.
Blood samples to measure plasma sitagliptin concentrations and plasma DPP4 activity were taken at baseline, at 0.5, 1, 2, 4, 8, 12, 16 and 24 h after the first dose, and at 2, 4, 8, 16 and 24 h after the second, third and fourth doses. Sitagliptin concentrations were assayed by a high-turbulence liquid chromatography online extraction method and detected by mass spectroscopy (API 4000; Applied Biosystems, Toronto, ON, Canada) using selected reaction monitoring with a turbo-ionspray interface in the positive ion mode. Plasma DPP4 activity was assayed using a DPPIV-Glo Protease Assay (Promega, Madison, WI, USA), according to the manufacturer's instructions. More details regarding the bioanalytical assay are presented in the Electronic Supplementary Material.
Data Analysis
Population modelling of sitagliptin concentrations and DPP4 inhibition was performed in NONMEM software AUC area under the plasma drug concentration-time curve, AUC 0-? AUC from time zero to infinity, AUC i-j h AUC from i to j h, BID twice daily, C max maximum plasma drug concentration, OD once daily a AUC 0-24 h b AUC 0-12 h version 7.2 (Icon Development Solutions, Hanover, MD, USA) using the first-order conditional estimation method with the INTERACTION option implemented. Pharmacokinetic and pharmacodynamic analyses were performed simultaneously. Between-subject variability (BSV) was modelled using exponential functions. Statistical significance was set at p \ 0.01.
Model Selection/Evaluation
Selection between models was based on visual inspection of goodness-of-fit plots, including conditional weighted residuals (CWRES) [18] and predictive checks, the objective function value (OFV) and the precision of the parameter estimates. The minimum OFV provided by NONMEM, which is approximately equal to -2 9 log likelihood (-2LL), served as a guide during model design. A decrease in -2LL of 6.63 points for one additional model parameter was regarded as a significant model improvement, corresponding to a p value of 0.01 for nested models. For non-nested models, the Akaike information criteria (AIC), calculated as AIC = -2LL ? 2 9 NP, where NP is the number of parameters in the model, was used [19] . Precision of parameter estimates, expressed as 5th to 95th percentiles, were computed from the analysis of 200 bootstrap data sets (sampling with replacement). The bootstrap analysis was performed using Perl-speaks-NONMEM software [20] . Model parameter estimates were presented together with the corresponding relative standard errors (RSEs [%]), as a measure of parameter imprecision, which were computed from the results obtained from the bootstrap analysis. The quantified BSV was expressed as a coefficient of variation (CV [%]). Model performance was evaluated with visual predictive checks (VPCs) and numerical predictive checks (NPCs). Predictive checks were performed using the MATLAB environment (The Mathworks, Natick, MA, USA). The VPC was performed as follows. Two hundred simulated studies were simulated with the same design characteristics as those of the original study. At each time observation point, the 2.5th, 50th and 97.5th percentiles of the plasma sitagliptin concentration (C p ) and DPP4 activity were calculated for every simulated study. Then the 95 % predicted interval for the three percentiles (2.5th, 50th and 97.5th) was calculated and represented over time, together with the raw data.
The NPC was performed as follows. Two hundred simulated studies were simulated with the same design characteristics as those of the original study. The median, 2.5th and 97.5th percentiles were calculated for the following pharmacokinetic-pharmacodynamic descriptors:
(1) pharmacokinetic descriptors: C max(0-24 h) , C max (24- 
Pharmacokinetic-Pharmacodynamic Modelling
The disposition of sitagliptin in plasma was described with compartmental models parameterized in apparent volumes of distribution, inter-compartmental clearances and total elimination clearance. Selection was made between one-, two-and three-compartment models.
The following two steps were followed to establish the pharmacokinetic-pharmacodynamic model: a baseline model and a drug effect model.
Step 1: Baseline model. DPP4 activity (unbound) was best described by an ordinary differential equation (Eq. 1):
where k syn (zero order) and k deg (first order) are the synthesis and degradation rates, respectively. During homeostasis, this system remains in equilibrium, thus (Eq. 2):
where DPP4 0 is the baseline value of DPP4 (the homeostatic value).
Step 2: Drug effect model. Sitagliptin is a competitive, reversible and potent inhibitor of DPP4. Initially, simple pharmacodynamic models were evaluated, including a direct response model, a linear effect-concentrationresponse model, a log-linear effect-concentration model and E max models (with and without sigmoidicity-a Hill exponent different from 1). Since DPP4 is a factor that is endogenously produced and eliminated, the indirect response model structures were also assessed. More specifically, three strategies were evaluated using this class of models to reflect the observed decrease in DPP4 activity with drug administration. These strategies were (1) to inhibit the input [k syn ]; (2) to stimulate the output [k deg ÁDPP4(t)]; or (3) both effects simultaneously. The three of them were explored and evaluated using changes in the OFV. In the selected model, binding between sitagliptin and DPP4 affects the output rate (Eq. 3).
where E drug is the increasing Hill function (Eq. 4) of the sitagliptin C P :
where E max is the maximum effect, EC 50 is the drug concentration necessary to achieve 50 % of E max , and h is the Hill exponent (the sigmoid degree). In order to describe an observed rebound of DPP4 activity following recovery from sitagliptin-mediated inhibition, a delayed negative feedback loop (Eqs. 5 and 6) had to be included:
where k f regulates the delay of the feedback loop and c denotes the effect on it after changes in DPP4 activity. Figure 1 shows the schematic representation of the semimechanistic population pharmacokinetic-pharmacodynamic model of the sitagliptin effect on DPP4 for patients who underwent UCB transplantation.
Dose Regimen Exploration: Methods
Dose exploration was based on simulation of 1,000 patients at each of the following doses: 50, 100, 200, 400, 600, 800, 1,000 and 1,200 mg OD. Regimen exploration was based on the simulation of 1,000 patients dosed at 600 mg, using each of the following schedules: OD, twice daily (BID), three times daily (TID) and four times daily (QID).
Dose Regimen Optimization: Methods
Mathematical optimization is the selection of the conditions (in this instance, the dosing regimen) to maximize achievement of a set of criteria. Sitagliptin DPP4 inhibition can be maximized by increased frequency of administration and/or bigger doses. However, this produces an incrementally increased risk of side effects and toxicity. Therefore, the criterion that were defined were the minimum bi-dimensional space of the DPP4 AUC 0-24 h and the sitagliptin AUC 0-24 h . Using different simulated dosing schemes, both descriptors were calculated and faced in a scatter plot. The optimal dose was defined as the dose whose Euclidean distance to the origin ([0, 0]) is minimized. Population simulations were generated using different doses from 100 to 1,200 mg in increments of 100 mg in the OD, BID, TID and QID regimens. The sitagliptin C max and AUC 0-24 h and the DPP4 AUC 0-24 h were calculated for every dose/scheme.
Results
Pharmacokinetic Model
The disposition of sitagliptin in plasma was best described by a two-compartment model, with drug absorption as a first-order rate constant. A lag in absorption was not supported by the data. BSV was significant for the apparent total plasma clearance (CL/F), apparent volume of distribution in the central compartment (V C /F), apparent volume of distribution in the peripheral compartment (V P /F) and relative bioavailability (F), for which the typical value was fixed at 1 (p \ 0.01). No pharmacokinetic parameters were time dependent or dose dependent. Covariance between random effects associated with the pharmacokinetics was not significant. Covariate effects were not explored. Table 2 lists the parameter estimates corresponding to the selected pharmacokinetic model, together with the corresponding 90 % confidence intervals obtained from the nonparametric bootstrap analysis. None of the confidence Fig. 1 Schematic representation of the selected pharmacokineticpharmacodynamic model. Pharmacokinetics: CL/F is the apparent plasma clearance (oral); k a is the first-order rate constant of absorption; Q/F is the inter-compartmental distribution clearance; V C /F and V P /F are the apparent volumes of distribution in the central and the peripheral compartments, respectively. Pharmacodynamics: dipeptidyl peptidase-4 (DPP4) activity (free receptor) can be synthesized at a zero-order rate (k syn ) and degraded at a first-order rate (k deg ). C P is the predicted plasma sitagliptin concentration; EC 50 is the drug concentration need to achieve 50 % of the E max ; E drug induces activity loss by the receptor binding. E max is the maximum effect; h is the Hill exponent. 1/k f represents the expected time delay for the feedback intervals included zero. The g-shrinkage values were 24.3 % (CL/F), 18.41 % (V C /F), 14.27 % (V P /F) and 4.67 % (F); the e-shrinkage value was 4.38 %. Individual model predictions with the corresponding patient observations of plasma sitagliptin concentrations are plotted in Fig. S1 (in the Electronic Supplementary Material). Figure 2 shows the goodness-of-fit plots, which indicate that the selected model properly describes the sitagliptin observations. Similar results were obtained from the NPC (see Table 3 ). The calculated percentiles of all pharmacokinetic descriptors (C max(0-24 h) , C max(24-48 h) , C max(48-72 h) , C max(72-96 h) , sitagliptin AUC \24 h , AUC \48 h , AUC \72 h and AUC \96 h ) from the simulated data were very similar to the corresponding percentiles calculated from the raw data (Table 3 ). In Fig. 3a , the VPC corresponding to the 4 days of treatment, shows that both the typical profiles and data dispersion were captured well by the model. Figure 1 shows the schematic representation of the selected semi-mechanistic population pharmacokinetic-pharmacodynamic model of the sitagliptin effect on DPP4 for patients who underwent UCB transplantation. While other drug effect models were explored (see Sect. 2), a binding process between sitagliptin and DPP4, affecting the output rate, best described the observations. The inclusion of a negative feedback loop was strongly supported by the observed data, although this has not been previously reported in the literature (p \ 0.01). BSV was identified for DPP4 0 , k syn and EC 50 . Table 2 also list the parameter estimates corresponding to the pharmacodynamic model and the corresponding 90 % confidence intervals obtained from the nonparametric bootstrap analysis. None of the confidence intervals included zero. The g-shrinkage values were 20.31 % (DPP4 0 ), 12.53 % (k syn ) and 4.27 % (EC 50 ); the e-shrinkage value was 5.07 %. Inclusion of covariance (positive correlation) between the random effect associated with EC 50 and the bioavailability (F) parameter significantly improved the OFV (-2LL). Individual model predictions and observed DPP4 levels for every patient are plotted in Fig. S2 (in the Electronic Supplementary Material). Figure 2 shows the goodness-of-fit plots for the selected model. The results of the NPC are shown in Table 4 . The calculated percentiles of all pharmacodynamic descriptors (Nadir 0-24 h , Nadir 24-48 h , Nadir 48-72 h , Nadir 72-96 h , DPP4 c feedback exponent, x 2 variance, BSV between-subject variability expressed as a coefficient of variation, CL/F total apparent oral clearance, Cov covariate, DPP4 0 baseline value for dipeptidyl peptidase-4 activity, EC 50 drug concentration necessary to achieve 50 % of the E max , E max maximum effect, F oral bioavailability, h Hill exponent, k a first-order rate constant of absorption, k f regulation of the delay of the feedback loop, k syn synthesis rate of DPP4, Q/F inter-compartmental distribution clearance between the central and peripheral compartments, RLU relative light units, RSE relative standard error, V C /F apparent volume of distribution in the central compartment a All parameters were simultaneously estimated and are listed here with their corresponding RSEs b Additive error model in log scale AUC \24 h , AUC \48 h , AUC \ 72 h and AUC \96 h ) from the simulated data were very similar to the corresponding percentiles calculated from the raw data (Table 4 ). Figure 3b , the VPC corresponding to DPP4 values during the period of treatment, shows that the typical profiles and data dispersion were accurately captured by the model.
Pharmacokinetic-Pharmacodynamic Model
Inter-occasion variability was evaluated, but no tendency or differences were found in any of the model parameters, including no change in the OFV. Data exploration showed no variability or tendency within the 4 days of DPP4 inhibitor administration (Tables 3, 4 ). Figure 4 shows the relationship described by the model (Eq. 4) between the plasma sitagliptin concentration and the drug effect as a percentage. At the dose of 600 mg (the dose utilized in the first phase of the clinical trial), the predicted maximum concentration after one single dose produced almost 80 % of the maximum possible drug effect. Simulated maximum concentrations achieved by other doses (50, 100, 200, 400, 800, 1,000 and 1,200 mg) are also indicated in Fig. 4 .
Dose Regimen Exploration
Four different pharmacokinetic-pharmacodynamic descriptors were calculated from model simulations changing the dose and the dosing schedule: (1) pharmacokinetics: C max(0-24 h) (ng/mL) and sitagliptin AUC 0-24 h (ngÁh/mL); (2) pharmacodynamics: Nadir 0-24 h (RLU) and DPP4 AUC 0-24 h (RLUÁh). Figure 5 shows dose-dependent changes in these descriptors from 1,000 simulated individuals at each of the following doses: 50, 100, 200, 400, 600, 800, 1,000 and 1,200 mg OD. When the dosage was increased to 1,200 mg OD, the sitagliptin C max(0-24 h) increased by 84.34 % and the AUC 0-24 h increased by 81.01 %, with respect to the reference dose of 600 mg OD; the DPP4 activity minimum value, Nadir 0-24 h , decreased by 17.08 %; and the DPP4 area under the activity-time curve, AUC 0-24 h , diminished by 18.77 %. Figure 6 shows the schedule-dependent changes in the same descriptors, based on 1,000 simulated individuals dosed at 600 mg, using each of the following schedules: OD, BID, TID and QID (x-axis). With BID dosing (a 1,200 mg total daily dose) the sitagliptin C max(0-24 h) increased by 17.86 % and the sitagliptin AUC 0-24 h increased by 90.10 %; the maximum DPP4 suppression (Nadir 0-24 h ) remained similar (increasing by only 4.24 %) and the DPP4 AUC 0-24 h decreased by 41.34 %, compared with the reference schedule of 600 mg OD. Figure S3 (in the Electronic Supplementary Material) shows this same analysis for a 200 mg dose. Because of the linearity of the pharmacokinetics, the increments for the C max(0-24 h) and the sitagliptin AUC 0-24 h were similar to those for the 600 mg dose. However, the DPP4 AUC 0-24 h diminished by only 41.34 %.
Dose Regimen Optimization
Population simulations of different doses and schedules were performed to maximize DPP4 inhibition (the DPP4 (Fig. 7a) and the DPP4 AUC 0-24 h versus the sitagliptin AUC 0-24 h (Fig. 7b) were compared for the OD, BID, TID and QID schedules with the different doses.
Because of the linearity of the pharmacokinetics, the relationship between the sitagliptin AUC 0-24 h and C max(0-24 h) for different doses of sitagliptin (doses from 100 to 1,200 mg in increments of 100 mg OD, BID, TID and QID) is described by straight lines. Depending on the number of doses per day (OD, BID, TID or QID), their slopes change. That is, as the number of doses per day increases, the lines have higher slopes (Fig. 7a ). There is a significant difference between the OD slope and the rest of the dosage frequencies. In other words, similar drug exposures-sitagliptin AUC 0-24 h values-are achieved with significantly lower maximum plasma concentrations-C max(0-24 h) values-when the same amount of the drug is administered as divided doses 2, 3 or 4 times per day. Comparing the OD, BID, TID and QID regimes with same daily dose, the 1,200 mg daily doses for the BID, TID and QID regimes produce the same C max(0-24 h) as the OD 600 mg daily dose, but the sitagliptin AUC 0-24 h (Fig. 7a ) is doubled compared with that produced by OD dosing. Interestingly, daily doses of 600 mg using the BID, TID and QID regimes produce sitagliptin AUC 0-24 h values similar to those produced by the OD 600 mg dose, but the DPP4 AUC 0-24 h decreases by approximately 33 % when BID, TID or QID dosing is used (Fig. 7b) . Mathematically, the optimal dosages (as defined by the Euclidean distances; see Sect. 2) were 500 mg TID (a 1,500 mg daily dose) and 400 mg QID (a 1,600 mg daily dose). If we assume that the number of doses per day as a third variable is to be minimized, then the optimal dosage is 500 mg TID (a 1,500 mg daily dose). It can be observed that the resulting DPP4 AUC is close to the mathematically optimal dosages.
Discussion
DPP4 cleaves a variety of endogenous proteins, regulating their activity [8, 21, 22] . Relevant to HCT, stromal-derived b The dipeptidyl peptidase-4 (DPP4) AUC 0-24 h versus the sitagliptin AUC 0-24 h . The optimal dosages are (1) 500 mg TID (a 1,500 mg daily dose) and (2) 400 mg QID (a 1,600 mg daily dose) [indicated by arrows]. The selected dose for the multicentre phase II trial (600 mg BID) is marked with an asterisk. RLU relative light units factor-1a and several colony-stimulating factors (e.g. granulocyte macrophage colony-stimulating factor, granulocyte colony-stimulating factor, interleukin-3 and erythropoietin) are regulated through DPP4 [2, 5, 23] . All play key roles in production and engraftment of haematopoietic cells in the bone marrow. Therefore, inhibition of DPP4 activity is an appealing strategy to increase engraftment efficiency in patients undergoing HCT. This is particularly relevant when the stem cell dose is limited, as is the case with UCB, where a low cell dose has been shown to increase transplant-related mortality and survival [24] [25] [26] . On the basis of preclinical data showing that treatment of mice with sitagliptin enhanced haematopoietic stem cell and haematopoietic progenitor cell recovery in a manner comparable to that seen in DPP4-null mice [5] , a clinical trial was initiated using oral sitagliptin in adult subjects undergoing single-unit UCB HCT [9] . The clinical trial participants whose data informed this pharmacokineticpharmacodynamic model had a median time to engraftment of 21 days, shorter than the majority of single-unit UCB HCTs reported in the literature [9] . The results showed that sitagliptin can be successfully repurposed for a new clinical indication, e.g. DPP4 inhibition may be a viable strategy to increase engraftment efficiency.
Sitagliptin is a US FDA-approved selective DPP4 inhibitor with minimal toxicity [28] . The trial dose was based on data from healthy volunteers, showing greater than 90 % DPP4 activity inhibition at 24 h following a single 600 mg dose [10] . However, in the HCT trial, the observed DPP4 inhibition was less than anticipated, with DPP4 activity returning to 80 % or more of baseline activity by 16 h. This emphasizes that in a different clinical context, the clinical pharmacology of therapeutics can change. Therefore, we developed a population pharmacokinetic-pharmacodynamic model that described the relationship between plasma sitagliptin concentrations and DPP4 activity in patients with haematological malignancies after single-unit UCB HCT in adult patients with leukaemia and lymphoma.
The kinetics of sitagliptin have been studied extensively-a summary of pharmacokinetic parameters is presented in Table 1 . Exposure, as described by the AUC 0-24 h and C max , is approximately twice as high in non-HCT populations as in the HCT population. Similarly, the clearance (dose/AUC 0-? ) of sitagliptin in non-HCT populations is 50 % slower than that reported by Farag et al. [9] . Unlike previously described populations, HCT patients are exposed to total body irradiation, high doses of chemotherapy and a variety of other therapeutics to condition the patients for HCT, manage symptoms, mitigate risks and prevent adverse consequences related to the transplant process-all of which may alter the way in which drugs behave in vivo [29] [30] [31] [32] . This may be particularly important in relation to sitagliptin activity, given that large-scale cell death following conditioning-regimen cytotoxic therapy is associated with large increases in DPP4 release from dying cells. Similarly, it is likely that physiological and pathophysiological processes and exposure to a number of concomitant medications can influence the absorption, distribution, metabolism and elimination of sitagliptin. In healthy volunteers, sitagliptin has high bioavailability (87 %), with absorption through both passive diffusion and active transport [17, 33, 34] . It has been previously shown that other oral drugs have significant changes in their pharmacokinetics as a result of changes such as mucositis, alterations in albumin and other proteins, or alterations in drug metabolism or transport [35] . Once the drugs are absorbed, there may be differences in protein binding. Sitagliptin has previously been shown to be 34-46 % protein bound [36] , and in HCT, albumin frequently declines over the course of transplantation-the total serum albumin levels in our study population were below normal (median 2.7 g/dL, normal range 3.2-5 g/dL). However, the effect of albumin (as a covariate) on sitagliptin pharmacokinetics was not studied, because of the design of the clinical trial. While metabolism plays a minor role in the disposition of sitagliptin in healthy volunteers and in patients with type 2 diabetes mellitus, with only 16 % of the administered dose being metabolized via cytochrome P450 (CYP) 3A and CYP2C8 [35] , it cannot be assumed that this remains the same in the HCT context. Elimination of sitagliptin is largely renal (87 %), via both glomerular filtration and active secretion, and both P-glycoprotein (MDR1/P-gp) and human organic anion transporter (hOAT)-3 have been shown to transport sitagliptin [12, 33, 34] . Beyond the potential for more rapid filtration due to a higher free drug fraction, there are also large fluid shifts in HCT, as well as extensive use of diuretics, which may impact sitagliptin clearance.
This latter point touches on another set of salient differences between non-HCT and HCT populations in regard to sitagliptin disposition-the potential for drug-drug interactions. Clinically significant drug-drug interactions are a known concern in HCT. In addition to the chemotherapeutics of the preparative conditioning regimens, HCT patients are on a cocktail of antibiotics, antifungals, immunosuppressants and other supportive care medications. In the pilot study by Farag et al. [9] , such medications included cyclophosphamide, tacrolimus, sirolimus, fluconazole, acyclovir and dexamethasone. Several of these drugs are known to have the potential for pharmacokinetic interactions at the level of metabolic enzymes and transporters. While it remains unclear whether there are clinically significant interactions between these drugs and sitagliptin, there are studies showing some potential for drug interactions [33, 34] . Our pharmacokinetic-pharmacodynamic model does not mechanistically describe all of these potential interactions, but it does accurately describe the profiles, allowing for refinement and optimization of the dose and dosing schedule of sitagliptin in HCT. Fludarabine replaced antithymocyte globulin following the first 11 patients, to reduce the risk of infection. As the available data were limited and the identity of those patients in the data set were not available to us, it was not possible to evaluate the effect of the replacement. In principle, this should not have an impact on the pharmacokinetics of sitagliptin, and no pharmacodynamic interactions between DPP4 and either fludarabine or antithymocyte globulin have been reported in the literature.
Simulation based on this model was then used to explore optimal dosing strategies for sitagliptin in HCT to maximize both the extent and the longevity of DPP4 inhibition. In mathematics, optimization is the selection of the best element with regard to some criteria from a set of available alternatives. Since sitagliptin is a DPP4 inhibitor, larger doses-as well as more frequent administration of the drug during the day-will produce greater DPP4 inhibition. Increments in the dose and the number of administrations also produce greater drug exposure, which may increase the probability of an adverse drug reaction. In this study, we defined just one criterion for optimizing this trade-off. We developed a scatter plot comparing the sitagliptin AUC and the DPP4 AUC with different dosing schemes, and we identified the dosage regimen that resulted in responses closest to the origin [0, 0]. Among the alternatives that were simulated with regard to the latest criterion, we found two optimal dosages: (1) 500 mg TID (a 1,500 mg daily dose) and (ii) 400 mg QID (a 1,600 mg daily dose). It is notable that the dose selected for the multicenter phase II trial (600 mg BID), based on additional, unpublished dosing cohorts defining the maximal tolerated dose (MTD) clinically, is very close to the optimal solutions (Fig. 7) . The trial dose going forward, defined by the MTD, is only 15 % less than the mathematically predicted optimal predicted dose in terms of DPP4 inhibition.
Interestingly, beyond the intended clinical application of this model, some questions of basic biology were raised. While DPP4 is known to be expressed on the surface of haematopoietic cells such as CD26, and as an active soluble form in plasma, the regulation of DPP4 expression is not fully characterized [21, 22, 37] . In order to capture the observed DPP4 activity in this trial, a feedback loop had to be incorporated to capture a rebound in DPP4 activity above baseline activity in the inter-dose intervals. While not previously reported in the literature, this feedback might represent a biological process in response to the rapid decline in DPP4 activity.
There are some limitations of our study conclusions that are secondary to the data characteristics that were used to build the models. The number of patients was small, and so BSV may not have been well defined, given the possibility that these individuals did not represent the full random distribution of the disposition or response across individuals. Another limitation was the use of a single dosing cohort. The use of different doses provides very informative data for model development, usually reducing the level of uncertainty and improving the precision of the parameter. Finally, a wide variety of disease subtypes were incorporated and, given the small total number of individuals, it was impossible to adequately assess whether there was a potential interaction between the disease kind/ state, the pharmacokinetics of sitagliptin and the DPP4 response. Despite these limitations, a small sample size and limited dosing cohorts are not uncommon in dense pharmacokinetic trials, and we do not expect a systematic disease-pharmacokinetics or disease-pharmacodynamics interaction. In addition to these data-and experiment-driven limitations, there are some limitations arising from the modelling approach. The modelling approach is potentially limited by being only semi-mechanistic. For instance, while we observed a feedback loop in DPP4 activity, a mechanistic explanation of this loop has not yet been described; therefore, this component of the model remains an empirical finding that was discovered during the modelbuilding process.
Conclusion
Sitagliptin pharmacokinetics in the HCT population are significantly lower (*50 %) with respect to profiles already published in the literature. This difference, which is probably due to the clinical context, highlights the need for such quantitative analysis-a valuable tool for the exploration of more optimal doses. Therefore, the data of Farag et al. [9] and the reported model-based analysis fill in critical clinical pharmacology information that is relevant to the repurposing of DPP4 inhibitors for this new indication. Furthermore, on the basis of model simulations, we explored dose regimens including OD, BID, TID and QID dosing of between 100 mg and 1,200 mg, looking for an optimal dose and dosing schedule to minimize DPP4 activity with minimal drug exposure (AUC). Our results indicate that the starting dose in the safety and tolerability clinical trial [9] , i.e. 600 mg OD, was an inefficient dose regimen. Indeed, any dose amount administered once daily is inferior in terms of maximizing DPP4 inhibition at the same total daily number of milligrams. This highlights the necessity of incrementing the frequency of the administration to at least a BID schedule.
